Search Results for “EU” – Page 381 – media

Sangamo Announces Treatment of First Patient in Landmark Phase 1/2 Clinical Trial Evaluating In Vivo Genome Editing for MPS II

Sangamo Therapeutics, Inc. (SGMO) today announced treatment of the first patient in the Phase 1/2 clinical trial ("the CHAMPIONS study") evaluating SB-913, an investigational in vivo genome editing therapy for people with mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome.
- Source: finance.yahoo
- 417
- November 17, 2017
Company Insight Hunter syndrome MPS II
Salt raises blood pressure, but our gut bacteria can stop it

It's a known fact that too much salt can increase blood pressure. But new research brings gut bacteria into the mix, and some good news along with it: probiotics may help to reverse the harmful effects of excessive salt.
- Source: medicalnewstoday
- 708
- November 17, 2017
blood pressure cardiovascular gut bacteria New Approvals
Jardiance is the first and only oral type 2 diabetes medicine approved to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.

New data presented today showed that Jardiance® reduced the risk of cardiovascular death compared with placebo when added to standard of care in adults with type 2 diabetes and peripheral artery disease.
- Source: finance.yahoo
- 607
- November 17, 2017
cardiovascular diabetes Jardiance® peripheral artery disease
How common are flu shot side effects?

With fall well underway and winter just around the corner, chances are your doctor, pharmacist, and maybe even your mom are telling you it's time to roll up your sleeve for a flu shot. If you're inclined to ignore them, we get it: No one really enjoys being jabbed with a needle.
- Source: foxnews
- 506
- November 17, 2017
flu shot
Medical first-Doctors attempt to gene-edit a living patient’s DNA

A man may soon be forever free of the previously incurable disease he was born with 44 years ago. On Monday, in a medical first, Brian Madeux received an experimental in-body gene-editing treatment intended to cure him of Mucopolysaccharidoses II, known as MPS II or Hunter syndrome, a rare disorder that causes progressive damage to the body's cells.
- Source: flipboard
- 428
- November 16, 2017
enzyme Hunter syndrome Market Views mucopolysaccharides
New dye gives scientists a clearer insight into the brain

Keele University researchers have designed a new dye that can be used to observe the electrical activity of neurons in the brain and could lead to finding a new and more efficient way of treating neurological diseases, as presented at the Society for Neuroscience annual conference in Washington, D.C. this week.
- Source: sciencedaily
- 409
- November 16, 2017
neurological Researches
Loxo Oncology Lands $1.55B Cancer Tie-Up With Bayer

Loxo Oncology struck a deal with Germany-based Bayer AG to develop and commercialize two cancer therapies in a deal that could be worth up to $1.55 billion for the Connecticut-based company.
- Source: Biospace
- 832
- November 16, 2017
cancer larotrectinib Market Views therapy TRK
Cholesterol Crystals Are Sure Sign A Heart Attack May Loom

A new Michigan State University study on 240 emergency room patients shows just how much of a role a person's cholesterol plays, when in a crystallized state, during a heart attack.
- Source: scienmag
- 535
- November 15, 2017
atherosclerosis cholesterol coronary arteries Researches
AstraZeneca-FASENRA Gets US FDA Approval For Severe Eosinophilic Asthma

AstraZeneca and its global biologics research and development arm, MedImmune, said Tuesay that the US Food and Drug Administration has approved FASENRA (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. FASENRA is not approved for the treatment of other eosinophilic conditions or relief of acute bronchospasm or status asthmaticus.
- Source: businessinsider
- 568
- November 15, 2017
asthma eosinophilic Market Views New Approvals
US regulators approve first digital pill to track patients

US regulators have approved the first drug with a sensor that alerts doctors when the medication has been taken, offering a new way of monitoring patients but also raising privacy concerns. The digital pill approved Monday combines two existing products: the former blockbuster psychiatric medication Abilify—long used to treat schizophrenia and bipolar disorder—with a sensor tracking system first approved in 2012.
- Source: medicalxpress
- 506
- November 15, 2017
bipolar disorder blockbuster New Approvals psychiatric schizophrenia

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.